The skeletal disease osteoporosis affects primarily postmenopausal women. It is characterized by increased fracture risk due to defective remodeling of bone tissue and a pathological bone microarchitecture in response to the decreased levels of estrogen. Osteoporosis is clinically silent up until a first fracture occurs. Therefore, the diagnosis of the disease is usually late. Recent preclinical studies with mice, rats and rabbits suggested that estrogen treatment enhances the healing effect after bone fractures. Here we asked whether transdermally applied estrogen, which restores the systemic premenopausal level of estrogen, has a beneficial effect on fracture healing of postmenopausal women as observed in preclinical models.
To investigate whether estrogen has a beneficial effect on bone fracture healing of postmenopausal patients, we performed a prospective double-blinded randomized study with 76 patients suffering from distal radius fractures. A total of 31 patients (71.13 years ± 11.99) were treated with estrogen and 45 patients (75.62 years ± 10.47) served as untreated controls. Calculated bone density as well as cortical bone density were determined by peripheral quantitative computed tomography (pQCT) prior to and six weeks after the surgery.
We found that unlike with preclinical models, bone fracture healing of human patients was not improved in response to estrogen treatment. Furthermore, we observed no dependence between age-dependent bone tissue loss and constant callus formation in the patients.
Transdermally applied estrogen to postmenopausal women, which results in estrogen levels similar to the systemic level of premenopausal women, has no significant beneficial effect on bone fracture healing.

Figure 1
Figure 2

Figure 3

Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
On 09 Oct, 2020
On 05 Oct, 2020
On 04 Oct, 2020
On 04 Oct, 2020
Invitations sent on 05 Aug, 2020
On 05 Aug, 2020
Received 05 Aug, 2020
On 03 Aug, 2020
On 02 Aug, 2020
On 02 Aug, 2020
Posted 01 Jun, 2020
On 22 Jul, 2020
Received 21 Jul, 2020
Received 13 Jul, 2020
On 01 Jul, 2020
On 29 Jun, 2020
Received 09 Jun, 2020
On 08 Jun, 2020
Invitations sent on 03 Jun, 2020
On 22 May, 2020
On 21 May, 2020
On 21 May, 2020
On 21 May, 2020
On 09 Oct, 2020
On 05 Oct, 2020
On 04 Oct, 2020
On 04 Oct, 2020
Invitations sent on 05 Aug, 2020
On 05 Aug, 2020
Received 05 Aug, 2020
On 03 Aug, 2020
On 02 Aug, 2020
On 02 Aug, 2020
Posted 01 Jun, 2020
On 22 Jul, 2020
Received 21 Jul, 2020
Received 13 Jul, 2020
On 01 Jul, 2020
On 29 Jun, 2020
Received 09 Jun, 2020
On 08 Jun, 2020
Invitations sent on 03 Jun, 2020
On 22 May, 2020
On 21 May, 2020
On 21 May, 2020
On 21 May, 2020
The skeletal disease osteoporosis affects primarily postmenopausal women. It is characterized by increased fracture risk due to defective remodeling of bone tissue and a pathological bone microarchitecture in response to the decreased levels of estrogen. Osteoporosis is clinically silent up until a first fracture occurs. Therefore, the diagnosis of the disease is usually late. Recent preclinical studies with mice, rats and rabbits suggested that estrogen treatment enhances the healing effect after bone fractures. Here we asked whether transdermally applied estrogen, which restores the systemic premenopausal level of estrogen, has a beneficial effect on fracture healing of postmenopausal women as observed in preclinical models.
To investigate whether estrogen has a beneficial effect on bone fracture healing of postmenopausal patients, we performed a prospective double-blinded randomized study with 76 patients suffering from distal radius fractures. A total of 31 patients (71.13 years ± 11.99) were treated with estrogen and 45 patients (75.62 years ± 10.47) served as untreated controls. Calculated bone density as well as cortical bone density were determined by peripheral quantitative computed tomography (pQCT) prior to and six weeks after the surgery.
We found that unlike with preclinical models, bone fracture healing of human patients was not improved in response to estrogen treatment. Furthermore, we observed no dependence between age-dependent bone tissue loss and constant callus formation in the patients.
Transdermally applied estrogen to postmenopausal women, which results in estrogen levels similar to the systemic level of premenopausal women, has no significant beneficial effect on bone fracture healing.

Figure 1
Figure 2

Figure 3

Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Loading...